Columbia University Minority/Underserved Site NCI Community Oncology Research Program

哥伦比亚大学少数族裔/服务欠缺站点 NCI 社区肿瘤​​学研究计划

• 批准号: 10673181
• 负责人: Jennifer E. Amengual
• 金额: $ 102.1万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-08-01 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10673181
• 关键词: Advisory Committees; Age; Cancer Burden; Cancer Center; Cancer Control; Cancer Patient; Catchment Area; Clinical Research; Clinical Trials; Clinical Trials Network; Collaborations; Communities; Community Clinical Oncology Program; Community Health; Continuity of Patient Care; Enrollment; Ethnic Origin; Gender; Goals; Health Personnel; Herbert Irving Comprehensive Cancer Center; Individual; Infrastructure; Institutional Review Boards; Lead; Leadership; Medical center; Minority; Minority Groups; Minority Participation; Patients; Phase; Population; Prevention; Quality of life; Race; Research; Role; Sex Orientation; Site; Socioeconomic Status; Therapeutic Trials; Tissues; Universities; base; biobank; cancer care; cancer clinical trial; cancer prevention; cancer therapy; care delivery; design; health care disparity; improved; novel therapeutics; outreach; patient population; programs; screening; underserved community

PROJECT SUMMARY The Herbert Irving Comprehensive Cancer Center’s Minority/Underserved National Community Oncology Research Program at Columbia University Irving Medical Center (HICCC/CUIMC/MU-NCORP) has established a robust infrastructure that facilitates the identification, activation and participation in NCORP Research Base clinical trials. The overall goal of the HICCC/CUIMC/MU-NCORP is to provide the best in cancer care to the minority/undeserved population that surrounds our cancer center. The specific aims of our program are to 1) Provide and enhance access for our community of patients and healthcare providers to a portfolio of NCI Clinical Trials Network (NCTN/NCORP) trials, specifically in the four components of cancer control, cancer prevention and screening, cancer care delivery (CCD) research and cancer treatment (Phase I, II, III) as well as tissue acquisition; 2) Enhance the accrual of minority and underserved patients onto these trials by promoting the accessibility and availability of the trial portfolio and identifying and reducing accrual barriers to meet the needs of our community, 3) Lead, participate, and promote NCORP/NCTN research base studies across the cancer care continuum with a particular focus on studies that reduce healthcare disparities, and 4) Collaborate and contribute to the NCI NCORP-wide activities. Over the past four years, this strong infrastructure has led to many accomplishments. Our MU-NCORP portfolio consists of over 150 trials, and we have enrolled over 500 patients to Cancer Control and Prevention, Cancer Care Delivery and Therapeutic Trials. We have consistently exceeded the minimum 30% accrual target for minority and underserved patient populations. In addition, we have taken leadership roles within the research bases and lead many trials. By facilitating the enrollment and participation of minority and underserved cancer patients into high impactful clinical trials, we will achieve our ultimate goal of improving survival and quality of life of all individuals regardless of age, race, ethnicity, gender, sexual orientation or socioeconomic status.

项目总结